 NEW YORK, Nov. 17, 2020 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Companys randomized, double-blind placebo-controlled Phase 3 trial... 